{
    "id": 2601,
    "fullName": "CCND1 positive",
    "impact": "unknown",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "CCND1 positive indicates the presence of the CCND1 gene, mRNA, and/or protein.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 595,
        "geneSymbol": "CCND1",
        "terms": [
            "CCND1",
            "BCL1",
            "D11S287E",
            "PRAD1",
            "U21B31"
        ]
    },
    "variant": "positive",
    "createDate": "11/19/2014",
    "updateDate": "12/11/2018",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 8785,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ML364 induced Ccnd1 degradation and inhibited survival of prostate cancer cells in a dose-dependent manner in culture (PMID: 27681596).",
            "molecularProfile": {
                "id": 2445,
                "profileName": "CCND1 positive"
            },
            "therapy": {
                "id": 4811,
                "therapyName": "ML364",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6749,
                    "pubMedId": 27681596,
                    "title": "Small Molecule Inhibition of the Ubiquitin-specific Protease USP2 Accelerates cyclin D1 Degradation and Leads to Cell Cycle Arrest in Colorectal Cancer and Mantle Cell Lymphoma Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27681596"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8784,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ML364 induced Ccnd1 degradation and inhibited survival of mantle cell lymphoma cells in a dose-dependent manner in culture (PMID: 27681596).",
            "molecularProfile": {
                "id": 2445,
                "profileName": "CCND1 positive"
            },
            "therapy": {
                "id": 4811,
                "therapyName": "ML364",
                "synonyms": null
            },
            "indication": {
                "id": 50746,
                "name": "mantle cell lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6749,
                    "pubMedId": 27681596,
                    "title": "Small Molecule Inhibition of the Ubiquitin-specific Protease USP2 Accelerates cyclin D1 Degradation and Leads to Cell Cycle Arrest in Colorectal Cancer and Mantle Cell Lymphoma Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27681596"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 943,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MRX34 (miR-34a) downregulated CCND1 to induce cell cycle arrest in a non-small cell lung cancer cell line in culture (PMID: 18406353).",
            "molecularProfile": {
                "id": 2445,
                "profileName": "CCND1 positive"
            },
            "therapy": {
                "id": 1035,
                "therapyName": "MRX34",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 618,
                    "pubMedId": 18406353,
                    "title": "Downregulation of CCND1 and CDK6 by miR-34a induces cell cycle arrest.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/18406353"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8783,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ML364 induced Ccnd1 degradation and inhibited survival of colorectal cancer cells in a dose-dependent manner in culture (PMID: 27681596).",
            "molecularProfile": {
                "id": 2445,
                "profileName": "CCND1 positive"
            },
            "therapy": {
                "id": 4811,
                "therapyName": "ML364",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6749,
                    "pubMedId": 27681596,
                    "title": "Small Molecule Inhibition of the Ubiquitin-specific Protease USP2 Accelerates cyclin D1 Degradation and Leads to Cell Cycle Arrest in Colorectal Cancer and Mantle Cell Lymphoma Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27681596"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8786,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ML364 induced Ccnd1 degradation and inhibited survival of breast cancer cells in a dose-dependent manner in culture (PMID: 27681596).",
            "molecularProfile": {
                "id": 2445,
                "profileName": "CCND1 positive"
            },
            "therapy": {
                "id": 4811,
                "therapyName": "ML364",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6749,
                    "pubMedId": 27681596,
                    "title": "Small Molecule Inhibition of the Ubiquitin-specific Protease USP2 Accelerates cyclin D1 Degradation and Leads to Cell Cycle Arrest in Colorectal Cancer and Mantle Cell Lymphoma Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27681596"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18276,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (PALOMA-3), CCND1 expression level did not correlate with response to addition of Ibrance (palbociclib) to Faslodex (fulvestrant) in patients with hormone receptor-positive, Erbb2 (Her2)-negative breast cancer, with hazard ratios for progression-free survival of Ibrance (palbociclib) versus placebo of 0.471 and 0.594 (p=0.503) in CCND1 low and high expression groups, respectively (PMID: 30807234; NCT01942135).",
            "molecularProfile": {
                "id": 33094,
                "profileName": "CCND1 pos ESR1 pos"
            },
            "therapy": {
                "id": 3205,
                "therapyName": "Fulvestrant + Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 16119,
                    "pubMedId": 30807234,
                    "title": "Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor-Positive Metastatic Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30807234"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 18277,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (PALOMA-3), CCND1 expression level did not correlate with response to addition of Ibrance (palbociclib) to Faslodex (fulvestrant) in patients with hormone receptor-positive, Erbb2 (Her2)-negative breast cancer, with hazard ratios for progression-free survival of Ibrance (palbociclib) versus placebo of 0.471 and 0.594 (p=0.503) in CCND1 low and high expression groups, respectively (PMID: 30807234; NCT01942135).",
            "molecularProfile": {
                "id": 33095,
                "profileName": "CCND1 pos PGR pos"
            },
            "therapy": {
                "id": 3205,
                "therapyName": "Fulvestrant + Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 16119,
                    "pubMedId": 30807234,
                    "title": "Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor-Positive Metastatic Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30807234"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        }
    ],
    "molecularProfiles": [
        {
            "id": 2445,
            "profileName": "CCND1 positive",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26900,
            "profileName": "CCND1 pos ERBB2 neg ESR1 pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 33094,
            "profileName": "CCND1 pos ESR1 pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 33095,
            "profileName": "CCND1 pos PGR pos",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}